Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Journal for ImmunoTherapy of Cancer is Scopus-indexed (Q1, CiteScore 16.6), WoS SCIE, DOAJ. It is covered by India's One Nation One Subscription scheme, which pays the article processing charge for authors at eligible institutions. Published by BMJ Publishing Group.
Checked against the index lists dated .
ISSN 2051-1426Verify ISSN ↗
Publisher: BMJ Publishing Group
Cost to publish: APC covered for authors at ONOS-subscribed Indian institutions
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology | 13 / 328 | 96th | Q1 |
| Oncology | 27 / 428 | 93rd | Q1 |
| Immunology and Allergy | 18 / 234 | 92nd | Q1 |
| Molecular Medicine | 14 / 179 | 92nd | Q1 |
| Cancer Research | 20 / 233 | 91st | Q1 |
| Immunology | 22 / 243 | 91st | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription)
Yes — actively indexed in Scopus, coverage 2013–present, best quartile Q1, CiteScore 16.6.
Journal for ImmunoTherapy of Cancer is Q1 in Pharmacology (rank 13 of 328), Q1 in Oncology (rank 27 of 428) and Q1 in Immunology and Allergy (rank 18 of 234), by CiteScore 2025. It is ranked in 6 subject areas in all.
Journal for ImmunoTherapy of Cancer is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 16.6, which places it in quartile Q1 at the 96th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 4.114, quartile Q1, with an H-index of 155.
For authors at Indian institutions covered by One Nation One Subscription (ONOS), the article processing charge is paid by the scheme. The publisher lists an article processing charge of about US$2,490 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Journal for ImmunoTherapy of Cancer is published by BMJ Publishing Group. Its ISSN is 2051-1426.
Yes. ONOS also covers its article processing charge for authors at eligible institutions.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Journal for ImmunoTherapy of Cancer has an h-index of 185 and a 2-year mean of 9.59 citations per paper (OpenAlex). Its Scopus CiteScore is 16.6, quartile Q1. On 2-year citations it ranks #10 of 319 Scopus journals in Pharmacology.
Journal for ImmunoTherapy of Cancer published 704 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2026), authors are most often from China (44.4%), United States (24.1%) and Netherlands (3.9%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (0.3 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.